Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron Aug 23, 2024 7:22pm
207 Views
Post# 36194231

RE:RE:RE:In the pipeline...

RE:RE:RE:In the pipeline...

Mikee3003 wrote: In the pipeline....lol!

Get real....bladder is the end game for Theralase. We are either successful with bladder or we go bankrupt. All these woopdie doo news releases of late mean squat and the market agrees!

To believe that Theralase will be around in 10 years is just not realistic....swim or sink time people. If we swim with bladder we will be bought out, if we sink........I suppose the kool aid gang will have their excuses....lol!

GLTA

BTW - hope we swim and a pharma with $$ and the know how can do what it takes to further this technology.



Funding is obviously tough for most small biotechs, many of which raise sufficient money to simply get them through the year or to the next milestone.  However, each milestone warrants a different degree of investor interest/money.  As the study progresses, each successive milestone achieved will generally demand much more interest/friendly funding.  I believe getting to BTD status will certainly be a funding inflection point & end the perpetual cycle of underwhelming PPs.
 

I don't see a path of failure in reaching BTD status due to a lack of funding.  Connected investors & management simply have too much skin in the game.  Having said that, management salary should be a reflection of company culture & success. 

Imo, an executive officer of any promising startup needs to gain trust from those within the company & from all of those invested.  Thus, I believe an executive officer should be the last one in the company to make a market rate salary.  This payment philosophy/structure signals to everyone you're putting your company first before yourself.  It emphasizes to all invested that the officer isn't committed to a biotech venture simply for a high salary, but rather for the greater good that also comes with a well-deserved/handsome payoff down the road...a goal we "all" wish for.

Budget-wise, if push comes to shove, it is my belief that our upper management/officers would take fiscal accountability & adjust salary/salaries in order to get this amazing science to the finish line...officers & investors simply have too much to lose otherwise...JMHO.


 

<< Previous
Bullboard Posts
Next >>